10-Q: Hi-Great Group Q1 2026 Financial Results

Hi-Great Group Holding Company reports a net loss of $7,830 for the first quarter of 2026 as it continues development-stage operations.

Summary

• Reported net loss of $7,830 for the three months ended March 31, 2026, compared to a loss of $18,938 in the same period of 2025.
• Generated $13,255 in sales for the quarter, up from $8,883 in the prior year period.
• Operating expenses totaled $13,186, primarily driven by professional fees.
• Cash position improved to $5,092 as of March 31, 2026, from $521 at year-end 2025.
• Accumulated deficit stands at $987,832, reflecting the company's development-stage status.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the company's status as a development-stage entity with material weaknesses in internal controls and a heavy reliance on related-party funding.

Positives

• Year-over-year reduction in net loss from $18,938 to $7,830.
• Increase in quarterly sales revenue to $13,255.
• Improved cash balance compared to the end of the previous fiscal year.

Negatives

• Continued net losses and significant accumulated deficit of $987,832.
• Lack of an audit committee and inadequate segregation of duties identified as material weaknesses in internal controls.
• Heavy reliance on related-party transactions for licensing and property leasing.

Risks

• Going concern uncertainty due to lack of sufficient revenue to cover operating costs.
• Dependence on debt and equity financing to sustain operations.
• Potential impact of COVID-19 on business combination efforts.
• Material weaknesses in internal controls over financial reporting.
• Concentration of risk in related-party agreements with SellaCare, Inc. and Sella Property, LLC.

Future Outlook

The company intends to focus on its exclusive global licensing agreement regarding the KRAS gene, continue marketing SellaCare, Inc. supplements, and expand into the cosmetic sector while seeking additional capital to fund operations.

Management Comments

• Management believes it will be successful in its capital formation and planned operating activities.
• The company is unable to predict the ultimate impact of COVID-19 at this time.

Industry Context

StockSavvy.ai notes that the company operates as a micro-cap development-stage entity with significant reliance on related-party intellectual property, which is common for shell-to-operating transitions but carries high execution risk compared to established biotech or consumer health firms.

Comparison to Industry Standards

• The company's reliance on related-party licensing is atypical for mature public companies and suggests a high degree of insider control.
• The lack of an audit committee is a significant deviation from standard corporate governance practices for publicly traded entities.

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Licensing agreement with SellaCare, Inc. for 25% of gross revenue.
• Land lease with Sella Property, LLC, an entity controlled by the majority shareholder.
• Notes payable to related parties totaling $83,250.

Stakeholder Impact

• Shareholders face significant dilution risk and going concern uncertainty.
• Creditors are exposed to the company's inability to generate sufficient cash flow.

Next Steps

• Continue efforts to raise additional equity capital.
• Advance business combination efforts.
• Market and distribute SellaCare, Inc. products.

Key Dates

Recommendation

The company exhibits classic signs of a distressed development-stage entity, including material weaknesses in governance, recurring losses, and heavy reliance on related-party transactions, making it unsuitable for most institutional or conservative retail investors.

Keywords

development stage, biotech, agritourism, herbal supplements, KRAS gene, related party transactions